Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204–5.
O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27(2):95–112.
Baron R, Binder A. [How neuropathic is sciatica? The mixed pain concept]. Orthopade. 2004;33(5):568–75.
Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–20.
Alles SRA, Smith PA. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018;70(2):315–47.
Cruccu G, Truini A. A review of Neuropathic Pain: From Guidelines to Clinical Practice. Pain Ther. 2017;6(Suppl 1):35–42.
Kumar N, Laferriere A, Yu JS, et al. Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem. 2010;113(2):552–61.
Annemans L, Caekelbergh K, Morlion B, et al. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg. 2008;63(3):170–8.
Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin. 2007;23(10):2585–96.
Gianesello L, Pavoni V, Barboni E, et al. Perioperative Pregabalin for Postoperative Pain Control and Quality of Life After Major Spinal Surgery. J Neurosurg Anesthesiol. 2011. 10.1097/ANA.0b013e31823a885b [doi].
Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology. 2005;183(2):133–43.
Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628–38.
Baidya DK, Agarwal A, Khanna P, et al. Pregabalin in acute and chronic pain. J Anaesthesiol Clin Pharmacol. 2011;27(3):307–14.
Deeks ED. Mirogabalin: First Global Approval. Drugs. 2019;79(4):463–8.
Domon Y, Arakawa N, Inoue T, et al. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the alpha2delta Subunit of Voltage-Gated Calcium Channels. J Pharmacol Exp Ther. 2018;365(3):573–82.
Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.
Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27(1):117–26.
Sakai Y, Ito K, Hida T, et al. Neuropathic pain in elderly patients with chronic low back painand effects of pregabalin: a preliminary study. Asian Spine J. 2015;9(2):254–62.
Yamashita T, Takahashi K, Yonenobu K, et al. Prevalence of neuropathic pain in cases with chronic pain related to spinal disorders. J Orthop Sci. 2014;19(1):15–21.
Ogawa S. Development of new screening questionnaire to identify neuropathic components in Japanese patients with chronic pain. Pain Clinic. 2010;31:1187–94.
Javed S, Petropoulos IN, Alam U, et al. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6(1):15–28.
Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res. 2018;11:1559–66.
Guidelines for the Pharmacologic Management of Neuropathic Pain Second Edition. Publication Department, Shinko Trading Co. Ltd.; 2016.
Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013;154(11):2249–61.
Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758–65.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–35.
Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10(5):1299–306.
Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160(5):1175–85.
Saeki K, Yasuda SI, Kato M, et al. Analgesic effects of mirogabalin, a novel ligand for alpha2delta subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(6):723–8.
Boroujerdi A, Zeng J, Sharp K, et al. Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. Pain. 2011;152(3):649–55.
Li CY, Song YH, Higuera ES, et al. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24(39):8494–9.
Li CY, Zhang XL, Matthews EA, et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125(1–2):20–34.
Edvardson S, Oz S, Abulhijaa FA, et al. Early infantile epileptic encephalopathy associated with a high voltage gated calcium channelopathy. J Med Genet. 2013;50(2):118–23.
Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006;103(46):17537–42.
Barclay J, Balaguero N, Mione M, et al. Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells. J Neurosci. 2001;21(16):6095–104.
Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253–61.
Nikaido T, Sumitani M, Sekiguchi M, et al. The Spine painDETECT questionnaire: Development and validation of a screening tool for neuropathic pain caused by spinal disorders. PLoS One. 2018;13(3):e0193987.